Nonetheless, the combination of anti‐LRP6 and anti‐DKK1 antibodies provided superior protection against myeloma‐induced bone loss, as well as providing superior protection against myeloma‐induced vertebral fracture compared to the single treatment approach. The gene discussed is DKK1; the disease is plasma cell myeloma.